secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0000950170-24-029667
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharma reports Q4 net loss $8.0M; cash $127M after $116M raise; CRB-701 shows 43% ORR
--------------------------------------------------------------------------------

- Net loss Q4 $8.0M ($1.81/diluted) vs $10.9M ($2.61) YoY; full year loss $44.6M ($10.31).
- Cash, equivalents & investments $127M as of Feb 2, 2024 after $116M capital raise; runway 3+ years through Q1 2027.
- CRB-701 (Nectin-4 ADC) Ph1 data: 43% ORR, 71% DCR at >=2.7 mg/kg; no DLTs, neuropathy, or skin rash. US Ph1 patient dosing starts March 2024.
- FDA cleared IND for CRB-601 (TGFβ blocker); Ph1 start summer 2024. CRB-913 (CB1 inverse agonist) IND filing on track for Q4 2024.
- Appointed Dr. Dominic Smethurst as CMO, previously CMO of Bicycle Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024029667/0000950170-24-029667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024029667/crbp-20240312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer